



Short Bio/CV

Sydney Tang is currently Chair of Renal Medicine and Yu Professor in Nephrology at The University of Hong Kong (HKU). He has served numerous functional and leadership roles at nephrology societies and organizations. At the *ISN*, he chaired the CME Program Committee (2022-2024), and serves the N&E Asia Regional Board (from 2014), ISN-ACT Trial Design Working Group and Network (from 2018), Core Program Committee (2018-2024), Nominating Committee (2018-2021), and Meetings Committee (2017-2019). At the *Asian Pacific Society of Nephrology (APSN)*, he was Hon Treasurer (2008-2016) and President (2022-2024) during which he fostered networking with the ISN (to support various capacity building programs around the Asia-Pacific region), ISPD, KDIGO and Saving Young Lives Committee. At the *HK Society of Nephrology*, he served as Chairman from 2016-2018. At the *ISPD*, he served the Publication Committee (2018). At *KDIGO*, he was on the Executive Committee from 2020-2023 and serves as a key member of the Clinical Practice Guideline on IgA nephropathy. At the *International Society of Glomerular Disease (ISGD)*, he is one of the founding members and Co-Chair, Peer Support Group. He is a Co-chair of the Funding Development Committee, *International IgA Nephropathy Network (IIGANN)* Research Group, and a Committee Member of the *International Home Dialysis Consortium*.

At international nephrology congresses, he was President of the Asian Pacific Congress of Nephrology 2020 (virtually in HK, China); Deputy Chair, Local Organizing Work Group, WCN'23 (Thailand); Scientific Program Executive Committee, ISPD Congress 2024 (Dubai); Deputy Chair of Program Committee, WCN'25 (India) and has been appointed by the ISN as Chair of Program Committee, WCN'26 (Japan).

He has been invited to deliver keynote lectures at major conferences including ASN Kidney Week, ERA Congress, WCN, ISPD, TTS, IDF, APCN, and Massachusetts General Hospital and Brigham and Women's Hospital Combined Nephrology Grand Round. His editorial responsibilities include Associate Editor (from 2024) of *JASN*, Theme and Subspecialties Editor (Clinical Nephrology and Diabetes) (2013-2023) of *NDT*, Editor-in-Chief (2018-2022) of *Nephrology (Carlton)*, and Editorial Board member of *KI*, *CJASN*, *American Journal of Nephrology*, and *Kidney Diseases*.

Sydney Tang graduated from HKU with MBBS, MD and PhD, and trained in clinical nephrology in HK and in basic sciences at King's College London, UK and the University of Washington, USA. He is an established clinician-scientist with major research interests on the pathogenetic mechanisms of diabetic and proteinuric CKD, AKI, treatment of IgA nephropathy, and is a national leader of multiple international RCTs in IgA nephropathy & other glomerulonephritides. He is active in mentoring research postgraduate (PhD, MPhil and MD) students at HKU for which he has received the Outstanding Research Student Supervisor Award in 2024. He has published over 330 SCI articles (GS *h*-index 71) and over 30 book chapters. His group's major scientific discoveries include MMF treatment for Chinese IgA nephropathy patients (*KI* 2005, 2010), the role of Toll-like receptor-4 in the diabetic kidney (*JASN* 2021, *KI* 2013, *Nat Rev Nephrol* 2020) and the role of long-noncoding RNA Neat1 in AKI (*JASN* 2024). He received the HKU Outstanding Researcher Award in 2017.

Candidate's Statement

I will assist and work with the Regional Board Chairman to advance the growth of nephrology and improve kidney health in our region and beyond. Specifically, I will focus on 1) **Communication** between our region and ISN: to disseminate information of ISN initiatives to our region, to receive board members' ideas, uphold our interests and reflect our needs to the ISN leadership, and to communicate/collaborate with other RBs; 2) **Advocacy/Awareness**: to raise awareness about kidney health issues and advocate for policies on early detection and prevention of AKI/CKD; 3) **Continuous Education/Training**: to support nephrologists, trainees and related healthcare professionals, such as nurses, to enhance provision of quality care to patients, including supporting the ISN CME Committee in nominating speakers when needed; 4) **Research/Innovation**: to promote research initiatives and collaboration to advance understanding and treatment of kidney diseases; 5) **Patient-oriented Support**: to advocate for patients' and carers' needs and for improved access to quality kidney replacement therapy; 6) **Collaboration/Networking**: to foster collaboration with other nephrology organizations and industry partners to leverage resources in mitigating kidney health challenges; 7) **Succession Planning**: to engage suitable individuals to join the RB. Regular board meetings (online/in-person) will be held to achieving all these 7 goals.